We studied the ability of Cryptococcus neoformans to produce the hexitol D-mannitol in vitro and in rabbits with experimental meningitis. Twelve of twelve human isolates of C. neoformans produced D-mannitol in yeast nitrogen base plus 1% glucose and released D-mannitol into the medium. In a pilot study, pooled cerebrospinal fluid (CSF) from cortisone-treated rabbits given 3 x 107 C. neoformans H99 intracisternally contained more D-mannitol (identified by gas chromatography and enzymatically) than CSF from normal controls or cortisone-untreated rabbits with self-limited meningitis. In a second experiment, cortisone-treated rabbits given C. neoformans intracisternally had significantly higher CSF D-mannitol concentrations than controls given cortisone alone at 4, 6, and 8 days after infection. Moreover, log1o CSF D-mannitol correlated well with loglo CSF CFU (r = 0.81) and log1o CSF cryptococcal antigen titers (r = 0.78). Lastly, the initial volume of distribution and elimination half-life of D-mannitol given intracisternally to normal rabbits suggested that D-mannitol was distributed in total CSF and was removed by CSF bulk flow. Thus, C. neoformans produces D-mannitol in vitro and in vivo, and D-mannitol is a quantitative marker for experimental cryptococcal meningitis. D-Mannitol produced by C. neoformans may also contribute to brain edema and interfere with phagocyte killing by scavenging hydroxyl radicals.
The prevalence of cryptococcal meningoencephalitis has increased markedly in recent years, primarily because the human immunodeficiency virus epidemic has greatly expanded the population of patients with profoundly deficient cellular immunity. A serious problem among patients with the acquired immune deficiency syndrome (AIDS) and cryptococcosis is that most of these patients relapse after receiving antifungal therapy that cures most patients with other underlying diseases (11, 28) . This problem is compounded by the fact that AIDS patients who will eventually relapse cannot be differentiated reliably from those who will not by clinical or available laboratory criteria. It has therefore been proposed that all AIDS patients with cryptococcal meningitis should receive prolonged or even lifelong suppressive therapy with the toxic antifungal agent amphotericin B (11, 28, 29) . Much of the drug toxicity, inconvenience, and expense that this approach necessarily entails might be avoided if better quantitative methods for assessing the effects of treatment on fungal load were available.
It has long been known that many fungi produce large amounts of acyclic polyols (23) , and recent studies have shown that Candida and Aspergillus species produce sufficient amounts of their polyol metabolites in infected mammalian hosts to cause increased body fluid concentrations. For example, the Candida species responsible for almost all cases of human infection produce large amounts of the pentitol D-arabinitol in vitro (2, 3, 10) , and animals (24) and humans (3, 9, 10, 20, 25, 27) with invasive candidiasis have more D-or DL-arabinitol in the serum than uninfected controls. It is also known that Candida albicans produces D-arabinitol in infected animals directly in proportion to fungal load (24) . Similarly, the Aspergillus species responsible for most cases of human aspergillosis produce large amounts of the hexitol D-mannitol in vitro (S. J. Flaherty, * Moreover, rats with experimental aspergillosis have higher D-mannitol levels in serum and tissue than uninfected controls, and these levels correlate well with severity of infection as assessed by histology (26) .
In 1968, Onishi and Suzuki (14) reported that a strain of Candida neoformans produced D-mannitol in culture, and the study by Flaherty et al. (Abstr. Annu. Meet. Am. Soc. Microbiol. 1984) confirmed this observation in a few additional strains. However, it is not known whether all or almost all strains of C. neoformans produce D-mannitol in vitro or whether any C. neoformans strain can produce appreciable amounts of D-mannitol in vivo. Therefore, we measured D-mannitol production by cultures of 12 human isolates of C. neoformans. We also analyzed cerebrospinal fluid (CSF) samples from rabbits with experimental cryptococcal meningitis to assess the ability of C. neoformans to produce D-mannitol in vivo.
(This work was presented in part at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Tex., 17 to 20 September 1989.) MATERIALS AND METHODS In vitro studies. We studied the abilities of 12 human isolates of C. neoformans to produce D-mannitol in vitro and to release it into the extracellular environment as follows. These strains included C. neoformans H99 (serotype A) and 11 24, 48 , and 96 h were also heated to 100°C for 10 min to release intracellular polyols (2) , and total D-mannitol (intracellular and extracellular) was measured.
Experimental cryptococcal meningitis. The ability of C. neoformans H99 to produce D-mannitol in vivo was studied by analyzing CSF from rabbits with cryptococcal meningitis (16) (14) .
D-Mannitol measurements. D-Mannitol in serum was measured by GC as described previously (26) (Fig. 1) .
Identification of D-mannitol in CSF. When the pooled CSF specimens were analyzed by GC, a compound with the same retention time as authentic D-mannitol was found in much larger amounts in the samples from the cortisone-treated, infected rabbits than in those from normal uninfected or non-cortisone-treated, infected rabbits. Treatment of the CSF samples with D-arabinitol dehydrogenase, lactate dehydrogenase, NAD, and sodium pyruvate resulted in the almost complete disappearance of the compound of interest, thus confirming its identification as D-mannitol (Fig. 2) . D-Mannitol production by C. neoformans in vivo. Among the rabbits studied in retrospect, the CSF D-mannitol concentrations corresponded well with severity of infection. The CSF colony counts declined over time in the noncortisone-treated rabbits given C. neoformans intracisternally, and CSF D-mannitol concentrations in these rabbits were no higher than the values in uninfected controls. In contrast, the CSF colony counts and CSF D-mannitol concentrations increased over time in the cortisone-treated rabbits given C. neoformans intracisternally (Fig. 3) . These results suggested that C. neoformans produced D-mannitol in proportion to fungal load, but specimens from cortisonetreated controls were unavailable.
Therefore, we next studied individual cortisone-treated rabbits given C. neoformans H99 intracisternally and corti- sone-treated, uninfected controls. The fungal colony counts, cryptococcal antigen titers, and D-mannitol concentrations in the infected and control rabbits are summarized in Fig. 4 .
The CSF D-mannitol concentrations rose substantially over time in the infected rabbits but not in the controls. The mean CSF D-mannitol concentrations (+SD) in the infected and control rabbits, respectively, were as follows: 1.91 ± 0.52 and 1.84 ± 0.34 ,uM on day -1 (n = 9 and 11, respectively; P = 0.675); 3.01 ± 0.56 and 2.60 ± 0.43 ,uM on day 2 (n = 7 and 9; P = 0.136); 7.03 ± 6.21 and 2.20 ± 0.40 ,uM on day 4 (n = 6 and 8; P = 0.008); 36.9 ± 21.6 and 2.14 ± 0.38 ,uM on day 6 (n = 5 and 8; P = 0.002); and 53.7 ± 37.4 and 2.43 ± 0.66 ,uM on day 8 after infection (n = 4 and 10; P = 0.001).
Among the infected rabbits, the CSF D-mannitol concentrations correlated well with severity of infection as assessed by CSF Distribution and elimination of D-mannitol in CSF. Since the rate at which a compound appears in a body compartment cannot be estimated from its concentration unless its distribution and rate of clearance are also known, we studied the distribution and elimination of D-mannitol in CSF. produced more D-mannitol during the stationary than during the logarithmic phase of the cultures, whereas C. albicans is a net producer of D-arabinitol during the logarithmic phase and a net utilizer of D-arabinitol thereafter (2) . We also found that C. neoformans released most of the D-mannitol it produced into the medium. C. albicans also releases most of the D-arabinitol it produces into the medium (2) (24) had much higher body fluid polyol levels than rats with disseminated aspergillosis (26) .
The ability of C. neoformans H99 to produce D-mannitol in vivo was studied in rabbits with experimental meningitis. In a pilot study of stored CSF specimens, the CSF D-VOL. 58, 1990 6r 1668 WONG ET AL. mannitol leveN corresponded well with severity of infection.
There was no more D-mannitol in the CSF of non-cortisonetreated rabbits with self-limited infection than in normal controls. In contrast, the CSF D-mannitol levels rose substantially in cortisone-treated rabbits with progressive infection. In a subsequent experiment in which individual rabbits given cortisone and C. neoformans H99 were compared with controls given cortisone alone, the CSF D-mannitol concentrations were much higher in the infected rabbits. Moreover, the CSF D-mannitol levels in infected rabbits rose directly in proportion to fungal load as assessed by CSF colony counts or CSF cryptococcal antigen titers. We also examined the distribution of D-mannitol within the CSF and its rate of elimination to facilitate interpretation of CSF D-mannitol concentrations. We found that (i) approximately 90% of D-mannitol given intracisternally was cleared during the first 4 h, (ii) the initial apparent volume of distribution approximated total CSF, and (iii) the initial elimination half-life was consistent with removal by bulk CSF flow. D-Mannitol was cleared more slowly after 4 h; possible explanations include uptake and slow release by tissues adjacent to the CSF or slow elimination from another body compartment that is in equilibrium with the CSF. These findings strongly suggest that C. neoformans H99 can produce large amounts of D-mannitol in vivo as well as in vitro. An alternative explanation for the results is that the excess D-mannitol in the CSF of infected rabbits may have been produced by the host as part of the inflammatory or immune response. We consider this unlikely, because (i) D-mannitol is not a known product of mammalian metabolism, (ii) the CSF D-mannitol levels were highly correlated with fungal load, and (iii) intracisternal inoculation of C. neoformans H99 results in lower CSF leukocyte counts and less intense meningeal inflammation in rabbits given cortisone than in cortisone-untreated controls (8, 16 Nevertheless, it is likely that CSF D-mannitol measurements should be more useful for some purposes than for others. Cryptococcosis differs from most other opportunistic mycoses in that reliable initial diagnostic methods are already available. C. neoformans can be isolated from the CSF of almost all infected patients, and the latex agglutination test for cryptococcal capsular polysaccharide antigen is a reliable and widely used initial diagnostic test. Moreover, increased CSF D-mannitol concentrations were not observed in the non-cortisone-treated infected rabbits or in the cortisone-treated infected rabbits until 4 days after infection. It therefore appears unlikely that CSF D-mannitol measurements will improve our ability to diagnose cryptococcal meningitis initially.
On the other hand, it is very difficult to assess the severity of cryptococcal meningitis by current diagnostic methods, especially during treatment (1, 5, 7) . For example, sterilization of the CSF within 2 weeks, pretreatment CSF cryptococcal antigen titers, and changes in CSF cryptococcal antigen titers over time correlated poorly with final outcome in a recent large treatment trial in patients with cryptococcal meningitis and a variety of underlying diseases (7) . Persistence of viable fungi outside the subarachnoid space and prolonged antigen shedding by dead or dying fungi were probably responsible for these findings.
In contrast, only actively metabolizing cryptococci produce D-mannitol, and dead fungi are unlikely to release substantial amounts of D-mannitol because little is conserved intracellularly. Also, since D-mannitol is cleared rapidly from the CSF, changes in fungal viability or metabolic activity should result in prompt changes in CSF Dmannitol concentrations. Thus, serial CSF D-mannitol measurements may provide a more precise means for quantifying the load of metabolically active fungi than is currently available, at least when the CSF D-mannitol concentrations are elevated initially. This approach should be most useful in patients in whom treatment is least likely to be successful (such as those with AIDS). In such patients, serial CSF D-mannitol measurements might eventually be used to individualize the dosages or durations of initial or suppressive antifungal therapy. This approach may also be helpful for assessing the likelihood of relapse or for comparing the effects of different forms of treatment on fungal viability or metabolic activity or both.
The results of the present study may also have pathogenetic implications. We have shown that D-mannitol accumulates in the CSF of infected rabbits despite an efficient clearance mechanism. Since D-mannitol is not metabolized by mammalian cells and since it crosses the blood-brain barrier by passive diffusion alone (18) , it is probably cleared less efficiently from brain tissue than from CSF. This suggests that there may be much more D-mannitol in tissues immediately surrounding actively metabolizing cryptococci than in CSF. One consequence of D-mannitol accumulation in brain tissue may be increased tonicity and edema. Cerebral edema is common in cerebral cryptococcosis (4), but its pathogenesis is poorly understood. Our results suggest that fungal production of a low-molecular-weight solute that is not easily cleared may be a contributing factor. It is also known that oxygen-dependent products of phagocytic cells (e.g., H202) kill C. neoformans in vitro (6) . Moreover, D-mannitol is an effective scavenger of hydroxyl radicals, and D-mannitol inhibits the abilities of hydroxyl radicals generated by xanthine oxidase and acetaldehyde to kill Staphylococcus aureus (10) and of monocytes and macrophages to kill Toxoplasma gondii (12) . Thus, accumulation of D-mannitol in infected tissues may also contribute to pathogenesis by interfering with optimal killing of C. neoformans by phagocytes.
In summary, we have shown that C. neoformans can produce large amounts of D-mannitol in vitro and in vivo. These results suggest that serial CSF D-mannitol measurements may be useful for quantifying fungal load in cryptococcal meningitis and that fungal D-mannitol production may contribute to the pathogenesis of cryptococcosis.
